Breast Cancer

  • Luis Chu
  • Eric P. Winer


Breast cancer is a common disease afflicting women in North America. The risk of developing breast cancer increases dramatically with age; women 65 years of age and older represent about 14% of the female population, but account for 43% of newly diagnosed breast cancers in the United States.1 Breast cancer in the elderly is commonly thought to be a more indolent disease, but relative survival in older women (65 years of age or older) diagnosed with breast cancer is lower than in younger women.1–3 Despite the predominance of older women with breast cancer, relatively little attention has been focused on treatment of patients in this age group. Most randomized studies have included few women over 65 years of age. Extrapolation of these results to the geriatric population may not be valid because of differences in tumor biology, host physiology, and problems common to older patients such as comorbidity, impaired functional status, and lack of social support.


Breast Cancer Breast Cancer Risk Metastatic Breast Cancer Axillary Lymph Node Dissection Breast Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yancik R, Ries LG, Yates JW. Breast cancer in aging women: a population-based study of contrasts in stage, surgery, and survival. Cancer. 1989; 63: 976–981.PubMedCrossRefGoogle Scholar
  2. 2.
    Adami H, Malker B, Holmberg L, et al. Relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986; 315: 559–563.PubMedCrossRefGoogle Scholar
  3. 3.
    Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer. 1986; 57: 2217–2221.PubMedCrossRefGoogle Scholar
  4. 4.
    Winso PA, Jong T, Bousen S. Cancer Statistics, 1995. CA Cancer J Clin. 1995; 45: 8–30.Google Scholar
  5. 5.
    Muir C, Waterhouse J, Mack T, et al., eds. Cancer Incidence in Five Continents, vol 5.1 ARC scientific publication 88. Lyon, France: International Agency for Research on Cancer; 1987.Google Scholar
  6. 6.
    National Center for Health Statistics. Mortality, Part A. Vital Statistics of the United States, 1987. Publication PHS 90–1101. Washington, DC: US Dept of Health and Human Services; 1990.Google Scholar
  7. 7.
    National Cancer Institute Statistics Review: 1975–1988. NIH publication 91–2789. Bethesda, MD: National Cancer Institute; 1991.Google Scholar
  8. 8.
    Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control 1991; 2: 67–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Miller BA, Ries LAG, Haney BF, et al. SEER Cancer Statistics Review: 1973–1990. NIH Publication 93–2789. Bethesda, MD: National Cancer Institute; 1993.Google Scholar
  10. 10.
    Harris JR, Lippman ME, Willett W. Breast cancer (part I). N Engl J Med. 1992; 327: 319–328.PubMedCrossRefGoogle Scholar
  11. 11.
    Lantz PM, Remington PL, Newcomb PA. Mammography screening and increased incidence of breast cancer in Wisconsin. J Natl Cancer Inst. 1991; 83: 1540–1546.PubMedCrossRefGoogle Scholar
  12. 12.
    Liff JM, Sung JF, Chow WH, et al. Does increased detection account for the rising incidence of breast cancer? Am J Public Health. 1991; 81: 462–465.PubMedCrossRefGoogle Scholar
  13. 13.
    Glass A, Hoover RN. Changing incidence of breast cancer. J Natl Cancer Inst. 1988; 80: 1076–1077.PubMedGoogle Scholar
  14. 14.
    Glass AG, Hoover RN. Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst. 1990; 82: 693–696.PubMedCrossRefGoogle Scholar
  15. 15.
    US Bureau of the Census. Current population reports, series P-25, no. 952. In: Projections of the Population of the United States by Age, Sex, and Race: 1983–2080. Washington, DC: US Government Printing Office; 1984.Google Scholar
  16. 16.
    Blot WJ, Devesa SS, Fraumeni JF. Declining breast cancer mortality among young American women. J Natl Cancer Inst. 1987; 78: 451–454.PubMedGoogle Scholar
  17. 17.
    Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer: prospective data from the nurses’ health study. JAMA. 1993; 270: 338–343.PubMedCrossRefGoogle Scholar
  18. 18.
    Kampert JB, Whittemore AS, Paffenbarger RS. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol. 1988; 128: 962–979.PubMedGoogle Scholar
  19. 19.
    White E. Projected changes in breast cancer incidence due to the trend toward delayed childbearing. Am J Public Health. 1987; 77: 495–497.PubMedCrossRefGoogle Scholar
  20. 20.
    Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972; 48: 605–613.PubMedGoogle Scholar
  21. 21.
    DuPont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312: 146–151.PubMedCrossRefGoogle Scholar
  22. 22.
    Boice JD, Monson RR. Breast cancer in women after repeated fluoroscopic examinations of the chest. J Natl Cancer Inst. 1977; 59: 823–832.PubMedGoogle Scholar
  23. 23.
    McGregor DH, Land CE, Choi K, et al. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950–69. J Natl Cancer Inst. 1977; 59: 799–811.PubMedGoogle Scholar
  24. 24.
    Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer. 1989; 44: 23–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Longnecker MP, Berlin JA, Orza MJ, et al. A metaanalysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988; 260: 652–656.PubMedCrossRefGoogle Scholar
  26. 26.
    Romieu I, Willett WC, Colditz GA, et al. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst. 1989; 81: 1313–1321.PubMedCrossRefGoogle Scholar
  27. 27.
    Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med. 1995; 332: 1589–1593.CrossRefGoogle Scholar
  28. 28.
    Willett W, Stampfer M, Colditz G. Dietary fat and risk of breast cancer. N Engl J Med. 1987; 316: 22–28.PubMedCrossRefGoogle Scholar
  29. 29.
    Jones G, Schatzkin A, Green S. Dietary fat and breast cancer in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. J Natl Cancer Inst. 1987; 79: 465–471.PubMedGoogle Scholar
  30. 30.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879–1886.PubMedCrossRefGoogle Scholar
  31. 31.
    Armstrong BK. Oestrogen therapy after menopause — boon or bane? Med J Aust. 1988; 148: 213–214.PubMedGoogle Scholar
  32. 32.
    DuPont WD, Page DL. Menopausal estrogen therapy and breast cancer. Arch Intern Med. 1991; 151: 67–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Steinberg KK, Thacker SB, Smith SJ, et al. A metaanalysis of the effect of estrogen therapy on the risk of breast cancer. JAMA. 1991; 265: 1985–1990.PubMedCrossRefGoogle Scholar
  34. 34.
    Sillero-Arenas M, Delgado-Rodríguez M, Rodrigues-Canteras R, et al. Menopausal hormone therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992; 79: 286–294.PubMedGoogle Scholar
  35. 35.
    Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993; 168: 1473–1480.PubMedGoogle Scholar
  36. 36.
    Key TJ, Pike MC. The role of oestrogens and progestins in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988; 24: 29–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Swanson CA, Brinton LA, Taylor PR, et al. Body size and breast cancer risk assessed in women participating in a breast cancer detection demonstration project. Am J Epidemiol. 1989; 130: 1133–1141.PubMedGoogle Scholar
  38. 38.
    Folsom AR, Kaye SA, Prineas RJ, et al. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990; 131: 794–803.PubMedGoogle Scholar
  39. 39.
    Schapira DV, Kumar NB, Lyman GH, et al. Abdominal obesity and breast cancer risk. Ann Intern Med. 1990; 112: 182–186.PubMedGoogle Scholar
  40. 40.
    Kirschner MA, Samojik E, Drejka M. Androgen-estrogen metabolism in women with upper body vs lower body adiposity. J Clin Endocrinol Metab. 1990; 70: 473–479.PubMedCrossRefGoogle Scholar
  41. 41.
    Newman B, Austin MA, Lee M, et al. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sei USA. 1988; 85: 3044–3048.CrossRefGoogle Scholar
  42. 42.
    Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991; 48: 232–242.PubMedGoogle Scholar
  43. 43.
    Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990; 250: 1684–1689.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith SA, Easton DF, Evans DGR, et al. Allele losses in the region 17ql2–21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet. 1992; 2: 128–131.PubMedCrossRefGoogle Scholar
  45. 45.
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1. Science. 1994; 266: 66–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993; 52: 678–701.PubMedGoogle Scholar
  47. 47.
    Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA 2, to chromosome 13ql2–13. Science. 1994; 265: 2088–2090.PubMedCrossRefGoogle Scholar
  48. 48.
    McGuire WL, Johnson BE, Seeger RC. Oncogenes in clinical cancer: a panel discussion. Breast Cancer Res Treat. 1987; 10: 217–227.PubMedCrossRefGoogle Scholar
  49. 49.
    Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177–182.PubMedCrossRefGoogle Scholar
  50. 50.
    Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319: 1239–1245.PubMedCrossRefGoogle Scholar
  51. 51.
    Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994; 330: 1260–1266.PubMedCrossRefGoogle Scholar
  52. 52.
    Jordan, VC. Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention. Cancer Treat Rev. 1990; 17: 15–36.PubMedCrossRefGoogle Scholar
  53. 53.
    Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977; 37: 1901–1907.PubMedGoogle Scholar
  54. 54.
    Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990; 15: 3–11.PubMedCrossRefGoogle Scholar
  55. 55.
    Stewart JA, Foster RS. Breast cancer and aging. Semin Oncol. 1989; 16: 41–50.PubMedGoogle Scholar
  56. 56.
    Satariano WA, Belle SH, Swanson GM. Severity of breast cancer at diagnosis: a comparison of age and extent of disease in black and white women. Am J Public Health. 1986; 76: 779–782.PubMedCrossRefGoogle Scholar
  57. 57.
    Dawson DA, Thompson GB. Breast Cancer Risk Factors and Screening: United States, 1987. Series 10: Data from the National Health Interview Survey, No. 172. Dept. of Health and Human Services publication 90–1550. Hyattsville, MD: National Center for Health Statistics; 1990.Google Scholar
  58. 58.
    Samet JM, Hunt WC, Lerchen ML, et al. Delay in seeking care for cancer symptoms: a population-based study of elderly New Mexicans./Natl Cancer Inst. 1988; 80: 432–438.Google Scholar
  59. 59.
    Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984; 2: 1102–1109.PubMedGoogle Scholar
  60. 60.
    Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120–1128.PubMedGoogle Scholar
  61. 61.
    Kiang DT, Kennedy BJ. Factors affecting estrogen receptors in breast cancer. Cancer. 1977; 40: 1571–1576.PubMedCrossRefGoogle Scholar
  62. 62.
    Elwood JM, Godolphin W. Oestrogen receptors in breast tumors: associations with age, menopausal status, and epidemiological and clinical features in 735 patients. Br J Cancer. 1980; 42: 635–644.PubMedCrossRefGoogle Scholar
  63. 63.
    Owens MA, Beardslee S, Wenger CR, et al. DNA ploidy and s-phase fraction by flow cytometry in a large breast cancer data base. Proc Am Assoc Cancer Res. 1990; 31: 184.Google Scholar
  64. 64.
    Schaefer G, Rosen PP, Lesser ML, et al. Breast carcinoma in the elderly woman: pathology, prognosis, and survival. Pathol Ann. 1984; 19: 195–219.Google Scholar
  65. 65.
    Schwab R, Walters CA, Weksler ME. Host defense mechanisms and aging. Semin Oncol 1989; 16: 20–27.PubMedGoogle Scholar
  66. 66.
    Manton KG, Wrigley JM, Cohen HJ, et al. Cancer mortality, aging, and patterns of comorbidity in the United States: 1968 to 1986. J Gerontol 1991; 46: 225–234.CrossRefGoogle Scholar
  67. 67.
    Mueller CB, Ames F, Anderson GD. Breast cancer in 3,558 women: age as a significant determinant in the rate of dying and causes of death. Surgery. 1978; 83: 123–132.PubMedGoogle Scholar
  68. 68.
    Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994; 120: 104–110.PubMedGoogle Scholar
  69. 69.
    Beahrs OH, Henson DE, Hutter RV, et al. Handbook for Staging of Cancer from the Manual for Staging of Cancer. 4th ed. Philadelphia: JB Lippincott; 1993: 161–167.Google Scholar
  70. 70.
    Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. TV Engl J Med. 1981; 305: 6–11.CrossRefGoogle Scholar
  71. 71.
    Sarrazin D, Le M, Rouesse J, et al. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. The experience of the Institut Gustave-Roussy. Cancer. 1984; 53: 1209–1213.PubMedCrossRefGoogle Scholar
  72. 72.
    Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989; 320: 822–828.PubMedCrossRefGoogle Scholar
  73. 73.
    Veronesi U, Banfi A, Del Vecchio M, et al. Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer. Eur J Cancer Clin Oncol 1986; 22: 1085–1089.PubMedCrossRefGoogle Scholar
  74. 74.
    NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991; 265: 391–395.CrossRefGoogle Scholar
  75. 75.
    Hunt KE, Fry DE, Bland KI. Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg. 1980; 140: 339–342.PubMedCrossRefGoogle Scholar
  76. 76.
    Amsterdam E, Birkenfeld S, Gilad A, et al. Surgery for carcinoma of the breast in women over 70 years of age. J Surg Oncol. 1987; 35: 180–183.PubMedCrossRefGoogle Scholar
  77. 77.
    Schain W, Edwards BK, Gorrell CR, et al. Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs. excisional biopsy and irradiation. Breast Cancer Res Treat. 1983; 3: 377–382.PubMedCrossRefGoogle Scholar
  78. 78.
    de Haes JC, van Oostrom MA, Welvaart K. The effect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur J Surg Oncol. 1986; 12: 337–342.PubMedGoogle Scholar
  79. 79.
    Lasry JC, Margolese RG, Poisson R, et al. Depression and body image following mastectomy and lumpectomy. J Chron Dis. 1987; 40: 529–534.PubMedCrossRefGoogle Scholar
  80. 80.
    Kemeny MM, Wellisch DK, Schain WS. Psychosocial outcome in a randomized surgical trial for treatment of primary breast cancer. Cancer. 1988; 62: 1231–1237.PubMedCrossRefGoogle Scholar
  81. 81.
    Christenson CV, Gagnon JH. Sexual behavior in a group of older women. J Gerontol. 1965; 20: 351–356.Google Scholar
  82. 82.
    Pfeiffer E, Verwoerdt A, Wang HS. Sexual behavior in aged men and women. Arch Gen Psychiatry. 1968; 19: 753–758.PubMedCrossRefGoogle Scholar
  83. 83.
    Vinokur AD, Threatt BA, Vinokur-Kaplan D, et al. The process of recovery from breast cancer for younger and older patients: changes during the first year. Cancer. 1990; 65: 1242–1254.PubMedCrossRefGoogle Scholar
  84. 84.
    Gazet JC, Markopoulos C, Ford HT, et al. Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988; 1: 679–681.PubMedCrossRefGoogle Scholar
  85. 85.
    Robertson JF, Todd JH, Ellis IO, et al. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. Br Med J. 1988; 297: 511–514.CrossRefGoogle Scholar
  86. 86.
    Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg. 1991; 78: 591–594.PubMedCrossRefGoogle Scholar
  87. 87.
    Horobin JM, Preece PE, Dewar JA, et al. Long-term fol-low-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991; 78: 213–217.PubMedCrossRefGoogle Scholar
  88. 88.
    Ciatto S, Bartoli D, Iossa A, et al. Response of primary breast cancer to tamoxifen alone in elderly women. Tumori. 1991; 77: 328–330.PubMedGoogle Scholar
  89. 89.
    Wyckoff J, Greenberg H, Sanderson R, et al. Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc. 1994; 42: 150–152.PubMedGoogle Scholar
  90. 90.
    Nemoto T, Patel JK, Rosner D, et al. Factors affecting recurrence in lumpectomy without irradiation for breast cancer. Cancer. 1991; 67: 2079–2082.PubMedCrossRefGoogle Scholar
  91. 91.
    Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993; 328: 1587–1591.PubMedCrossRefGoogle Scholar
  92. 92.
    Reed MW, Morrison JM. Wide local excision as the sole primary treatment in elderly patients with carcinoma of the breast. Br J Surg. 1989; 76: 898–900.PubMedCrossRefGoogle Scholar
  93. 93.
    Kantorowitz DA, Poulter CA, Sischy B, et al. Treatment of breast cancer among elderly women with segmental mastectomy or segmental mastectomy plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1988; 15: 263–270.PubMedCrossRefGoogle Scholar
  94. 94.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985; 312; 674–681.PubMedCrossRefGoogle Scholar
  95. 95.
    Pezner R, Patterson M, Hill L, et al. Arm lymphedema in patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys. 1986, 12: 2079–2083.PubMedCrossRefGoogle Scholar
  96. 96.
    Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1991; 9: 988–996.PubMedGoogle Scholar
  97. 97.
    Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 1994; 74: 878–883.PubMedCrossRefGoogle Scholar
  98. 98.
    Fisher B, Slack N, Katrych D. Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975; 140: 5–28.Google Scholar
  99. 99.
    Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer. 1978; 41: 11–70.CrossRefGoogle Scholar
  100. 100.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Part 1. Lancet. 1992; 339: 1–15.Google Scholar
  101. 101.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Part 2. Lancet. 1992; 339: 71–85.Google Scholar
  102. 102.
    Love, RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol. 1989; 7: 803–815.PubMedGoogle Scholar
  103. 103.
    Jordan VC. Estrogen-receptor mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990; 82: 1662–1663.PubMedCrossRefGoogle Scholar
  104. 104.
    Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res. 1990; 50: 4177–4189.PubMedGoogle Scholar
  105. 105.
    Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol. 1990; 8: 519–526.PubMedGoogle Scholar
  106. 106.
    Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long term follow-up and causes of death. J Clin Oncol. 1993; 11: 29–35.PubMedGoogle Scholar
  107. 107.
    Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Eng J Med. 1989; 320: 479–484.CrossRefGoogle Scholar
  108. 108.
    The Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988; 57: 608.CrossRefGoogle Scholar
  109. 109.
    Fisher B, Dignam J, Wieand S, et al. Duration of tamoxifen therapy for primary breast cancer: 5 versusGoogle Scholar
  110. 10.
    years (NSABP B-14). Proc Am Soc Clin Oncol. 1996; 15: 1–13.Google Scholar
  111. 110.
    Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1991; 83: 1299–1306.PubMedCrossRefGoogle Scholar
  112. 111.
    Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991; 115: 860–864.PubMedGoogle Scholar
  113. 112.
    McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J. 1991; 303: 435–437.CrossRefGoogle Scholar
  114. 113.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326: 852–856.PubMedCrossRefGoogle Scholar
  115. 114.
    Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994; 12: 992–997.PubMedGoogle Scholar
  116. 115.
    Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer. Lancet. 1989; 1: 117–120.PubMedCrossRefGoogle Scholar
  117. 116.
    Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527–537.PubMedCrossRefGoogle Scholar
  118. 117.
    Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994; 343: 1318–1321.PubMedCrossRefGoogle Scholar
  119. 118.
    Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term tamoxifen treatment can induce ocular toxicity. Cancer. 1992; 69: 2961–2964.PubMedCrossRefGoogle Scholar
  120. 119.
    Fisher B, Fisher ER, Redmond C. Ten-year results from the NSABP clinical trial evaluating the use of L- phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986; 4: 929.PubMedGoogle Scholar
  121. 120.
    Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med. 1995; 332: 901–906.PubMedCrossRefGoogle Scholar
  122. 121.
    Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989; 320: 473–478.PubMedCrossRefGoogle Scholar
  123. 122.
    Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med. 1989; 320: 485–490.PubMedCrossRefGoogle Scholar
  124. 123.
    Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990; 8: 1005–1018.PubMedGoogle Scholar
  125. 124.
    Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone in postmenopausal patients: Ludwig studies III and IV. In: Senn H, Goldhirsch A, Gelber RD, et al., eds. Recent Results in Cancer Research-Adjuvant Therapy of Primary Breast Cancer. Berlin: Springer-Verlag; 1989: 153–162.CrossRefGoogle Scholar
  126. 125.
    Henderson IC. Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast Diseases. 2nd ed. Philadelphia: JB Lippincott; 1991: 427–486.Google Scholar
  127. 126.
    Gelber RD and Goldhirsch A for the Ludwig Breast Cancer Study Group. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986; 4: 17–72.Google Scholar
  128. 127.
    Goldhirsch A, Gelber RD, Simes JR, et al., for the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989; 7: 36.PubMedGoogle Scholar
  129. 128.
    Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 1983; 52: 1986–1992.PubMedCrossRefGoogle Scholar
  130. 129.
    Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994; 12: 2447–2452.PubMedGoogle Scholar
  131. 130.
    Todd M, Shoag M, Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol. 1983; 1: 406–408.PubMedGoogle Scholar
  132. 131.
    Clark GM, Sledge GW, Osborne CK, et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol. 1987; 5: 55–61.PubMedGoogle Scholar
  133. 132.
    Baum M, Priestman T, West RR, et al. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. In: Mouridsen HT, Palshof T, eds. Breast Cancer — Experimental and Clinical Aspects. Oxford: Pergamon Press; 1980: 223.Google Scholar
  134. 133.
    Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med. 1987; 317: 14–90.CrossRefGoogle Scholar
  135. 134.
    Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988; 6: 1377.PubMedGoogle Scholar
  136. 135.
    A’hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer. 1988; 57: 615.PubMedCrossRefGoogle Scholar
  137. 136.
    Wong K, Henderson IC. Management of metastatic breast cancer. World J Surg. 1994; 18: 98–111.PubMedCrossRefGoogle Scholar
  138. 137.
    Whitliff JL. Steroid-hormone receptors in breast cancer. Cancer. 1984; 53: 630.CrossRefGoogle Scholar
  139. 138.
    Muss HB, Wells HB, Paschold EH, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis—a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988; 6: 1098–1106.PubMedGoogle Scholar
  140. 139.
    Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982; 42: 3430–3433.Google Scholar
  141. 140.
    Taylor SG, Gelman RS, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986; 104: 455–461.PubMedGoogle Scholar
  142. 141.
    Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast Diseases. 2nd ed. Philadelphia: Lippincott; 1991: 604–665.Google Scholar
  143. 142.
    Ibrahim N, Buzdar A, Frye D, et al. Should age be a determinant factor in treating breast cancer patients with combination chemotherapy? Proc Am Soc Clin Oncol. 1993; 12: 68.Google Scholar
  144. 143.
    Christman K, Muss HB, Case LD, et al. The relationship of age to treatment response in women with advanced breast cancer: the Piedmont Oncology Association experience. Proc Am Soc Clin Oncol. 1991; 10: 85.Google Scholar
  145. 144.
    Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984; 2: 1404–1413.PubMedGoogle Scholar
  146. 145.
    Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. JAMA. 1987; 257: 2766–2770.PubMedCrossRefGoogle Scholar
  147. 146.
    Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA. 1986; 255: 3385–3390.PubMedCrossRefGoogle Scholar
  148. 147.
    August DA, Rea TD, Sondak VK. Age related differences in breast cancer treatment. Society of Surgical Oncology, 46th Annual Cancer Symposium in conjunction with Society of Head and Neck Surgeons. 1993; 62.Google Scholar
  149. 148.
    Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992; 326: 1097–1101.PubMedCrossRefGoogle Scholar
  150. 149.
    Silliman RA, Guadagnoli E, Weitberg AB, et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989; 44: 46–50.CrossRefGoogle Scholar
  151. 150.
    Fetting JH, Comstock GW, Huelskamp A, et al. Treatment for metastatic breast cancer in a defined population: are the elderly underserved? Proc Am Soc Clin Oncol. 1993; 12: 475.Google Scholar
  152. 151.
    Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc. 1985; 33: 585–589.PubMedGoogle Scholar
  153. 152.
    Mann B A, Samet JM, Hunt WC, et al. Changing treatment of breast cancer in New Mexico from 1969 through 1985. JAMA. 1988; 259: 3413–3417.PubMedCrossRefGoogle Scholar
  154. 153.
    Goodwin JS, Samet JM. Care received by older women diagnosed with breast cancer. Cancer Control. 1994; 1: 313–319.PubMedGoogle Scholar
  155. 154.
    Goodwin JS, Hunt WC, Humble CG, et al. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988; 148: 2258–2260.PubMedCrossRefGoogle Scholar
  156. 155.
    Benson AB, Pregler JP, Bean JA, et al. Oncologists’ reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991; 9: 2067–2075.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Luis Chu
  • Eric P. Winer

There are no affiliations available

Personalised recommendations